Literature DB >> 93036

Metabolism of intravenously administered cholecalciferol in man.

J M Barragry, M W France, B J Boucher, R D Cohen.   

Abstract

Following intravenous injection of (3H) cholecalciferol into healthy subjects the disappearance of label from the plasma was followed by the reappearance ("rebound") of (3H) radioactivity associated exclusively with cholecalciferol. Lipoprotein fractionation of plasma revealed an increasing association of label with protein rather than lipoprotein during the rebound phase. We conclude that the rebound of plasma radioactivity reflects the transfer of label from lipoprotein to Vitamin D-binding globulin in the liver followed by its release into plasma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 93036     DOI: 10.1111/j.1365-2265.1979.tb03101.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Human plasma transport of vitamin D after its endogenous synthesis.

Authors:  J G Haddad; L Y Matsuoka; B W Hollis; Y Z Hu; J Wortsman
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

2.  Method for simultaneous analysis of eight analogues of vitamin D using liquid chromatography tandem mass spectrometry.

Authors:  Iltaf Shah; Andrea Petroczi; Declan P Naughton
Journal:  Chem Cent J       Date:  2012-10-01       Impact factor: 4.215

3.  Misleading measures in Vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars.

Authors:  Iltaf Shah; Ricky James; James Barker; Andrea Petroczi; Declan P Naughton
Journal:  Nutr J       Date:  2011-05-14       Impact factor: 3.271

4.  An ultrasensitive UHPLC-ESI-MS/MS method augmented with a controlled microwave derivatization reaction for quantitation of vitamin D3 and its major metabolites in COVID-19 patients.

Authors:  Sameh A Ahmed; Hani M J Khojah; Sultan S Al-Thagfan; Yaser M Alahmadi; Yasser A Mohammed
Journal:  Talanta       Date:  2022-04-22       Impact factor: 6.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.